CA2759063C — 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(n,n-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((s)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate and the use thereof
Assigned to Boehringer Ingelheim International GmbH · Expires 2012-04-17 · 14y expired
What this patent protects
The invention provides the compound 4-[(3-chloro-4- fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7- ((S)- tetrahydrofuran-3-yloxy)-quinazoline dimaleate. The compound may be used for treatment of a benign or malignant tumour, for preventing or treating…
USPTO Abstract
The invention provides the compound 4-[(3-chloro-4- fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7- ((S)- tetrahydrofuran-3-yloxy)-quinazoline dimaleate. The compound may be used for treatment of a benign or malignant tumour, for preventing or treating a disease of the respiratory tract and lungs or for treating a disease of the gastro-intestinal tract, or the bile duct and gall bladder. The invention also provides a process for preparing a dimaleate of 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1- oxo-2- buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, comprising: converting 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N, N-dimethylamino)-1-oxo-2-buten-1- yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline into the dimaleate by reacting with maleic acid in a suitable solvent, with heating.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.